Prospective, multicenter, randomized, double-blind, parallel-group, dose-response study of three doses Xeomin(incobotulinumtoxin - Rehabilitation Institute of Chicago

Skip to Content

Prospective, multicenter, randomized, double-blind, parallel-group, dose-response study of three doses Xeomin(incobotulinumtoxinA, NT 201) for the treatment of upper limb spasticity in children and adolescents(age 2-17 years) with cerebral palsy

Objective

To investigate efficacy and safety of Xeomin in subjects with upper limb spasticity alone or with combined upper limb and lower limb spasticity due to cerebral palsy. 

IRB Protocol Number
WIRB® Protocol #20131730
Principal Investigator(s)
Deborah Gaebler-Spira

Clinical Trial Categories

  • Brain Injury Research
  • Cerebral Palsy - Pediatrics Research

Compensation

  • Provided
Contact
Azra Cikmirovic at 312-238-1623
or acikmirovi@ric.org
Who Can Participate

Children and adolescents ages 2-17